High Quality Lamivudine CAS 134678-17-4 in Bulk Stock

Model NO.: 99%
Einecs No.: N/a
Character: White to off-White Powder
Mf: C8h11n3o3s
MW: 229.25
Purity: 99%
Quality Guarantee Period: Two Years Min
Grade Standard: Enterprise Standard
Sample: 10-20g Free Sample
Brand Name: Wongpharm
Trademark: wongpharm
Transport Package: 25kg/Drum
Specification: 99%
Origin: Zhejiang China (Mainlan)
Model NO.: 99%
Einecs No.: N/a
Character: White to off-White Powder
Mf: C8h11n3o3s
MW: 229.25
Purity: 99%
Quality Guarantee Period: Two Years Min
Grade Standard: Enterprise Standard
Sample: 10-20g Free Sample
Brand Name: Wongpharm
Trademark: wongpharm
Transport Package: 25kg/Drum
Specification: 99%
Origin: Zhejiang China (Mainlan)

Basic information
CAS No:134678-17-4                                                          Einecs No.:   N/A
Character:White to off-white  powder                           MF:C8H11N3O3S
MW:229.25                                                                         Purity:99%
Quality Guarantee Period:Two Years Min                      Grade Standard:enterprise standard
Sample:10-20g Free Sample                                             Brand Name:Wongpharm




Lamivudine CAS 134678-17-4
Specification: USP
Molecular formula:C8H11N3O3S
Character:White to off-white  powder
 

pharmacological toxicology:
lamivudine is a nucleoside antivirals.It has a strong inhibitory effect on the hepatitis b virus in vitro and in experimental infected animals.Lamivudine may be metabolized within infected cells and normal cells lamivudine triphosphate, it is the active form of lamivudine, is viral polymerase inhibitors, can quickly inhibit the replication of the virus.Lamivudine triphosphate seeps into the viral DNA strand and blocks the synthesis of viral DNA.Lamivudine triphosphate does not interfere with the metabolism of normal cell deoxynucleoside, and the inhibition of DNA polymerase alpha and beta in mammalian DNA has little effect on the DNA content of mammalian cells.Lamivudine has no obvious toxicity to mitochondrial structure, DNA content and function

pharmacokinetics:
 lamivudine was well absorbed after oral administration, and oral lamivudine 0.1g was estimated to be about 1 hour for blood peak concentration (Cmax), 1.1 ~ 1.5 ug/ml, and biological utilization was 80% ~ 85 %.Lamivudine and food can delay between 0.25 ~ 2.5 hours and the concentration of blood drug peak (Cmax) by 10 ~ 40%, but the bioavailability remains unchanged.Intravenous drug research results show that the average distribution of lamivudine (Vd) volume of 1.3 L/kg, average system clearance of 0.3 L/h/kg, lamivudine (70%), mainly by the organic cation transport system by renal clearance, blood elimination half-life (t1/2)
For 5 to 7 hours.The pharmacokinetic kinetics of lamivudine was linear in the therapeutic dose range, and the plasma protein binding rate was low.In vitro studies showed that the binding rate of serum albumin was <16% ~ 36%.Lamivudine can enter the cerebrospinal fluid through the blood-cerebrospinal barrier barrier.
Lamivudine is mainly based on the renal excretion of the drug prototype, and the renal excretion is about 70% of the total clearance, and only 5% ~ 10% is metabolized into the derivative of the anti-sulfur oxide.



drug interaction:
1. Lamivudine and have the same discharge mechanism of drugs (such as methyl benzyl oxygen organism, sulfamethoxazole) at the same time, when using lamivudine blood levels can be increased by 40%, but is damage to kidney function.
2. The concentration of blood drug peaks (Cmax) of the latter can be increased with zidovudine, but it does not affect the area under the curve of the elimination and drug.


Indications:
It is applicable to all kinds of virus infection
Usage and dosage:
take oral, 2 mg/kg weight, 1 time a day.
Storage: 
shade, seal, kept in a cool, dry place
Package:10kg/drum

 




specification

ASSAY ITEMS

SPECIFICATION(USP)

Appearance

White to off-white crystalline powder

Solubility

Soluble in water, sparingly soluble in ethanol, practically insoluble in ethyl acetate

Light Absorption

Not more than 0.0015 (440nm, 4cm cell, 50mg/ml)

Identification

A) The IR Spectrum of test sample corresponds to the standard IR spectrum of Lamivudine

B) The retention time of the major peak in the chromatogram of the test solution corresponds to that in chromatogram of the reference solution, as obtained in the test of Limit of Lamivudine enantiomer.

Water

Not more than 0.2%

Limit of Lamivudine Enantiomer

Not more than 0.3%

Residual Solvents

Ethanol is not more than 0.2%

Triethylamine (TEA) is not more than 0.1%

Dichloromethane is not more than 0.06%

Toluene is not more than 0.089%

N,N-Dimethylformamide is not more than 0.088%

n-Hexane is not more than 0.029%

Total residual solvents not more than 0.3%

Chromatographic Purity

Salicylic acid is not more than 0.10%

Relative retention time at about 0.4 impurity is not more than 0.3%

Relative retention time at about 0.9 impurity is not more than 0.2%

Any other individual impurity is not more than 0.1%

Total impurities

not more than 0.6%

HPLC Assay (Anhydrous basis)

Not less than 98.0% and not more than 102.0%

Basic information
CAS No:134678-17-4                                                          Einecs No.:   N/A
Character:White to off-white  powder                           MF:C8H11N3O3S
MW:229.25                                                                         Purity:99%
Quality Guarantee Period:Two Years Min                      Grade Standard:enterprise standard
Sample:10-20g Free Sample                                             Brand Name:Wongpharm




Lamivudine CAS 134678-17-4
Specification: USP
Molecular formula:C8H11N3O3S
Character:White to off-white  powder
 

pharmacological toxicology:
lamivudine is a nucleoside antivirals.It has a strong inhibitory effect on the hepatitis b virus in vitro and in experimental infected animals.Lamivudine may be metabolized within infected cells and normal cells lamivudine triphosphate, it is the active form of lamivudine, is viral polymerase inhibitors, can quickly inhibit the replication of the virus.Lamivudine triphosphate seeps into the viral DNA strand and blocks the synthesis of viral DNA.Lamivudine triphosphate does not interfere with the metabolism of normal cell deoxynucleoside, and the inhibition of DNA polymerase alpha and beta in mammalian DNA has little effect on the DNA content of mammalian cells.Lamivudine has no obvious toxicity to mitochondrial structure, DNA content and function

pharmacokinetics:
 lamivudine was well absorbed after oral administration, and oral lamivudine 0.1g was estimated to be about 1 hour for blood peak concentration (Cmax), 1.1 ~ 1.5 ug/ml, and biological utilization was 80% ~ 85 %.Lamivudine and food can delay between 0.25 ~ 2.5 hours and the concentration of blood drug peak (Cmax) by 10 ~ 40%, but the bioavailability remains unchanged.Intravenous drug research results show that the average distribution of lamivudine (Vd) volume of 1.3 L/kg, average system clearance of 0.3 L/h/kg, lamivudine (70%), mainly by the organic cation transport system by renal clearance, blood elimination half-life (t1/2)
For 5 to 7 hours.The pharmacokinetic kinetics of lamivudine was linear in the therapeutic dose range, and the plasma protein binding rate was low.In vitro studies showed that the binding rate of serum albumin was <16% ~ 36%.Lamivudine can enter the cerebrospinal fluid through the blood-cerebrospinal barrier barrier.
Lamivudine is mainly based on the renal excretion of the drug prototype, and the renal excretion is about 70% of the total clearance, and only 5% ~ 10% is metabolized into the derivative of the anti-sulfur oxide.



drug interaction:
1. Lamivudine and have the same discharge mechanism of drugs (such as methyl benzyl oxygen organism, sulfamethoxazole) at the same time, when using lamivudine blood levels can be increased by 40%, but is damage to kidney function.
2. The concentration of blood drug peaks (Cmax) of the latter can be increased with zidovudine, but it does not affect the area under the curve of the elimination and drug.


Indications:
It is applicable to all kinds of virus infection
Usage and dosage:
take oral, 2 mg/kg weight, 1 time a day.
Storage: 
shade, seal, kept in a cool, dry place
Package:10kg/drum

 




specification

ASSAY ITEMS

SPECIFICATION(USP)

Appearance

White to off-white crystalline powder

Solubility

Soluble in water, sparingly soluble in ethanol, practically insoluble in ethyl acetate

Light Absorption

Not more than 0.0015 (440nm, 4cm cell, 50mg/ml)

Identification

A) The IR Spectrum of test sample corresponds to the standard IR spectrum of Lamivudine

B) The retention time of the major peak in the chromatogram of the test solution corresponds to that in chromatogram of the reference solution, as obtained in the test of Limit of Lamivudine enantiomer.

Water

Not more than 0.2%

Limit of Lamivudine Enantiomer

Not more than 0.3%

Residual Solvents

Ethanol is not more than 0.2%

Triethylamine (TEA) is not more than 0.1%

Dichloromethane is not more than 0.06%

Toluene is not more than 0.089%

N,N-Dimethylformamide is not more than 0.088%

n-Hexane is not more than 0.029%

Total residual solvents not more than 0.3%

Chromatographic Purity

Salicylic acid is not more than 0.10%

Relative retention time at about 0.4 impurity is not more than 0.3%

Relative retention time at about 0.9 impurity is not more than 0.2%

Any other individual impurity is not more than 0.1%

Total impurities

not more than 0.6%

HPLC Assay (Anhydrous basis)

Not less than 98.0% and not more than 102.0%